Products with Hepatoprotective Bioactivity

Explore BioCrick products associated with Hepatoprotective biological activity, including catalog numbers, product names and available bioactivity information.

Hepatoprotective Bioactivity Products

Cat. No. Product Name
BCN4304 Kaerophyllin
1. Kaerophyllin can protect the rat liver from TAA-caused injury and fibrogenesis by suppressing hepatic inflammation and inhibiting HSC activation, possibly through upregulation of PPAR-γ expression. 2. Kaerophyllin inhibits AB-induced LX-2 activation and migration with downregulation of Akt/ERK phosphorylations and NF-κB activity.
BCN4320 Cleomiscosin A
1. Cleomiscosin A and brusatol are antitumor agents, have antileukemic principles. 2. Cleomiscosin A has antioxidant activity, it could be beneficial in preventing LDL oxidation in atherosclerotic lesions. 3. Cleomiscosin A methyl ether derivatives have anti-inflammatory activity. 4. Cleomiscosin A shows inhibitory activity to TNF-α secretion of the mouse peritoneal macrophages. 5. The mixture of three compounds (cleomiscosin A, B and C) is showing the significant protective effects against CCl(4)-induced hepatotoxicity in small animals and also coumarinolignoids are well tolerated by small animals in acute oral study.
BCN4385 Rutaecarpine
Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells.
BCN4388 Cleomiscosin C
1. Cleomiscosin C has antioxidant activity, it protects against the oxidative modification of apoB-100 induced by either Cu2+ or HOCl ( IC50s of 23.6 and 3.9 microM, respectively), suggests that it could be beneficial in preventing LDL oxidation in atherosclerotic lesions. 2. Cleomiscosins A, B and C exhibit liver-protective properties.
BCN4534 Limonexic acid
1. Limonexic acid shows antinociceptive actions , it produces dose-related inhibition of glutamate- and capsaicin-induced pain. 2. Limonexic acid can effectively protect hepatocyte against CCl4-induced injury.

Items 106 to 110 of 232 total